AngioDynamics Management
Management criteria checks 3/4
AngioDynamics' CEO is Jim Clemmer, appointed in Apr 2016, has a tenure of 8.08 years. total yearly compensation is $3.98M, comprised of 19% salary and 81% bonuses, including company stock and options. directly owns 0.97% of the company’s shares, worth $2.26M. The average tenure of the management team and the board of directors is 5.9 years and 8.2 years respectively.
Key information
Jim Clemmer
Chief executive officer
US$4.0m
Total compensation
| CEO salary percentage | 19.0% |
| CEO tenure | 8.1yrs |
| CEO ownership | 1.0% |
| Management average tenure | 5.9yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
Apr 09AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry
Apr 06
AngioDynamics: Restructuring Initiative May Not Go Far Enough
Jan 14AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Oct 12AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt
Mar 31AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance
Oct 06AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold
Sep 29Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?
Sep 02AngioDynamics Non-GAAP EPS of $0.01 in-line, revenue of $87M beats by $4.09M
Jul 12AngioDynamics Shows Progress In Still-Challenging Times
Apr 08Is AngioDynamics (NASDAQ:ANGO) Using Debt Sensibly?
Apr 08AngioDynamics - Progress Despite Margin And Pandemic Challenges
Feb 01Does AngioDynamics (NASDAQ:ANGO) Have A Healthy Balance Sheet?
Jan 07Shareholders May Not Be So Generous With AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Compensation And Here's Why
Oct 28Is AngioDynamics (NASDAQ:ANGO) Weighed On By Its Debt Load?
Oct 07AngioDynamics: Focusing On Three Credible Growth Drivers And Targeting Growth Acceleration
Jul 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Feb 29 2024 | n/a | n/a | -US$192m |
| Nov 30 2023 | n/a | n/a | -US$14m |
| Aug 31 2023 | n/a | n/a | US$6m |
| May 31 2023 | US$4m | US$756k | -US$52m |
| Feb 28 2023 | n/a | n/a | -US$37m |
| Nov 30 2022 | n/a | n/a | -US$33m |
| Aug 31 2022 | n/a | n/a | -US$33m |
| May 31 2022 | US$6m | US$736k | -US$27m |
| Feb 28 2022 | n/a | n/a | -US$40m |
| Nov 30 2021 | n/a | n/a | -US$38m |
| Aug 31 2021 | n/a | n/a | -US$34m |
| May 31 2021 | US$4m | US$720k | -US$32m |
| Feb 28 2021 | n/a | n/a | -US$169m |
| Nov 30 2020 | n/a | n/a | -US$171m |
| Aug 31 2020 | n/a | n/a | -US$170m |
| May 31 2020 | US$3m | US$716k | -US$167m |
| Feb 29 2020 | n/a | n/a | -US$7m |
| Nov 30 2019 | n/a | n/a | -US$6m |
| Aug 31 2019 | n/a | n/a | -US$7m |
| May 31 2019 | US$3m | US$687k | -US$11m |
| Feb 28 2019 | n/a | n/a | -US$34m |
| Nov 30 2018 | n/a | n/a | -US$16m |
| Aug 31 2018 | n/a | n/a | -US$12m |
| May 31 2018 | US$3m | US$643k | -US$6m |
| Feb 28 2018 | n/a | n/a | US$1m |
| Nov 30 2017 | n/a | n/a | -US$10m |
| Aug 31 2017 | n/a | n/a | US$4m |
| May 31 2017 | US$2m | US$625k | -US$7m |
Compensation vs Market: Jim's total compensation ($USD3.98M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Clemmer (59 yo)
8.1yrs
Tenure
US$3,983,691
Compensation
Mr. James C. Clemmer, also known as Jim, has been the Chief Executive Officer, President and a Director of AngioDynamics, Inc. since joining it on April 04, 2016. Mr. Clemmer served as Group President of t...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.1yrs | US$3.98m | 0.97% $ 2.3m | |
| Executive VP & CFO | 4.6yrs | US$1.25m | 0.22% $ 502.3k | |
| Senior VP and GM of Global Vascular Access & Oncology Global Business Unit | 8yrs | US$778.04k | 0.087% $ 202.7k | |
| Senior VP & GM of International | 2.9yrs | US$843.44k | 0.0083% $ 19.3k | |
| Vice President of Communications | 4.3yrs | no data | no data | |
| Senior Vice President of Business Development | 9.2yrs | no data | no data | |
| Senior Vice President of Human Resources | 4.7yrs | no data | no data | |
| Senior Vice President of Quality & Regulatory Affairs | 7.1yrs | US$897.17k | no data | |
| Senior Vice President of Information Technology | 12.7yrs | no data | no data | |
| Senior Vice President of Scientific & Clinical Affairs | 3.3yrs | no data | no data |
5.9yrs
Average Tenure
55yo
Average Age
Experienced Management: ANGO's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 8.1yrs | US$3.98m | 0.97% $ 2.3m | |
| Independent Director | 7.5yrs | US$224.50k | 0.15% $ 346.0k | |
| Independent Director | 17.3yrs | US$234.50k | 0.25% $ 575.2k | |
| Independent Non-Executive Chairman | 20.2yrs | US$262.00k | 0.30% $ 705.1k | |
| Independent Director | 8.3yrs | US$224.50k | 0.15% $ 344.2k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$224.50k | 0.11% $ 261.5k |
8.2yrs
Average Tenure
62.5yo
Average Age
Experienced Board: ANGO's board of directors are considered experienced (8.2 years average tenure).